Colorado PDAB Decisions Highlight Differing State Drug Board Structures

By Luke Zarzecki / February 21, 2024 at 2:40 PM
Updated Story How state bills creating prescription drug affordability boards (PDABs) define affordability result in varied scenarios for what could happen as the boards move forward. In Colorado, where the board focuses on affordability for consumers, manufacturers’ assistance programs have played a large role, specifically in determining whether Vertex’s Trikafta and Gilead Sciences’ Genvoya are affordable. Colorado’s PDAB voted that Trikafta, a therapy for cystic fibrosis that costs over $200,000 per patient, is “ not unaffordable ,”...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.